Payment overview · 2025
General Payments
$220.76
11 reported records · 7 companies
Healthcare provider profile · identity verified
Roy Loewenstein, MD
Allopathic & Osteopathic Physicians|Internal Medicine · TUCSON, AZ · NPI 1295793941
Verified facts
What the public records show
CMS Open Payments records show Roy Loewenstein, MD received $220.76 in general payments during 2025 across 11 reported records.
PFIZER INC. accounted for 20.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Rybelsus.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 178 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 101 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $46.10 | 20.9% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $44.42 | 20.1% | 3 | 2025 |
| SANOFI PASTEUR INC. | Unresolved — no canonical attribution shown | $41.72 | 18.9% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $32.24 | 14.6% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $25.03 | 11.3% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $16.76 | 7.6% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $14.49 | 6.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $220.76 | 11 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $46.10 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $46.10 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $46.10 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $44.42 | 3 | 2025 |
Source payment records
|
|||||
| FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE Normalized: flublok quadrivalent northern hemisphere |
Biological | SANOFI PASTEUR INC. | $41.72 | 2 | 2025 |
Source payment records
|
|||||
| FLUZONE HIGH-DOSE Normalized: fluzone high dose |
Biological | SANOFI PASTEUR INC. | $41.72 | 2 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $32.24 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $25.03 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $25.03 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $16.76 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $14.49 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $14.49 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 178 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
178 | 33 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
101 | 28 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
24 | 24 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 1052 | 347 |
| Losartan Potassium | Losartan Potassium | 588 | 184 |
| Amlodipine Besylate | Amlodipine Besylate | 574 | 198 |
| Atorvastatin Calcium | Atorvastatin Calcium | 458 | 144 |
| Levothyroxine Sodium | Levothyroxine Sodium | 456 | 140 |
| Pravastatin Sodium | Pravastatin Sodium | 344 | 110 |
| Gabapentin | Gabapentin | 290 | 102 |
| Lisinopril | Lisinopril | 286 | 86 |
| Hydrochlorothiazide | Hydrochlorothiazide | 262 | 88 |
| Alendronate Sodium | Alendronate Sodium | 241 | 87 |
| Tamsulosin Hcl | Tamsulosin Hcl | 236 | 74 |
| Pantoprazole Sodium | Pantoprazole Sodium | 215 | 79 |
| Omeprazole | Omeprazole | 183 | 76 |
| Metformin Hcl | Metformin Hcl | 180 | 57 |
| Sertraline Hcl | Sertraline Hcl | 179 | 59 |
| Ozempic | Semaglutide | 178 | 33 |
| Metoprolol Succinate | Metoprolol Succinate | 168 | 56 |
| Montelukast Sodium | Montelukast Sodium | 160 | 55 |
| Zolpidem Tartrate | Zolpidem Tartrate | 160 | 50 |
| Allopurinol | Allopurinol | 135 | 43 |
| Potassium Chloride | Potassium Chloride | 112 | 45 |
| Trazodone Hcl | Trazodone Hcl | 110 | 45 |
| Fluticasone Propionate | Fluticasone Propionate | 106 | 44 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 102 | 39 |
| Eliquis | Apixaban | 101 | 28 |
| Escitalopram Oxalate | Escitalopram Oxalate | 96 | 32 |
| Simvastatin | Simvastatin | 88 | 28 |
| Metoprolol Tartrate | Metoprolol Tartrate | 87 | 26 |
| Torsemide | Torsemide | 87 | 30 |
| Celecoxib | Celecoxib | 81 | 37 |
| Azithromycin | Azithromycin | 78 | 70 |
| Synthroid | Levothyroxine Sodium | 77 | 23 |
| Carvedilol | Carvedilol | 73 | 24 |
| Duloxetine Hcl | Duloxetine Hcl | 71 | 23 |
| Valsartan | Valsartan | 66 | 21 |
| Famotidine | Famotidine | 65 | 18 |
| Donepezil Hcl | Donepezil Hcl | 64 | 21 |
| Prednisone | Prednisone | 64 | 41 |
| Valacyclovir | Valacyclovir Hcl | 61 | 28 |
| Hydralazine Hcl | Hydralazine Hcl | 53 | 20 |
| Ezetimibe | Ezetimibe | 51 | 21 |
| Finasteride | Finasteride | 51 | 14 |
| Memantine Hcl | Memantine Hcl | 50 | 15 |
| Warfarin Sodium | Warfarin Sodium | 48 | 13 |
| Jardiance | Empagliflozin | 46 | 16 |
| Pregabalin | Pregabalin | 46 | 14 |
| Fluoxetine Hcl | Fluoxetine Hcl | 45 | 14 |
| Cephalexin | Cephalexin | 44 | 33 |
| Pioglitazone Hcl | Pioglitazone Hcl | 44 | 12 |
| Citalopram Hbr | Citalopram Hydrobromide | 42 | 13 |
| Dutasteride | Dutasteride | 42 | 16 |
| Lorazepam | Lorazepam | 42 | 21 |
| Spironolactone | Spironolactone | 42 | 16 |
| Trulicity | Dulaglutide | 42 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 40 | 13 |
| Mirtazapine | Mirtazapine | 39 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 38 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 37 | 11 |
| Furosemide | Furosemide | 35 | 13 |
| Atenolol | Atenolol | 34 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 32 | 19 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 32 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 31 | 23 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 29 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 28 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 28 | 13 |
| Clonidine Hcl | Clonidine Hcl | 27 | 16 |
| Fenofibrate | Fenofibrate | 26 | suppressed |
| Glipizide Er | Glipizide | 26 | 11 |
| Xarelto | Rivaroxaban | 26 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 24 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 24 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 24 | 24 |
| Sumatriptan Succinate | Sumatriptan Succinate | 24 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 24 | 16 |
| Buspirone Hcl | Buspirone Hcl | 23 | suppressed |
| Ondansetron Odt | Ondansetron | 23 | suppressed |
| Ramipril | Ramipril | 23 | suppressed |
| Irbesartan | Irbesartan | 21 | suppressed |
| Creon | Lipase/Protease/Amylase | 20 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 20 | 16 |
| Ondansetron Hcl | Ondansetron Hcl | 20 | 11 |
| Alprazolam | Alprazolam | 19 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 19 | 11 |
| Breo Ellipta | Fluticasone/Vilanterol | 18 | suppressed |
| Meloxicam | Meloxicam | 18 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 18 | 11 |
| Tradjenta | Linagliptin | 18 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 18 | 18 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 18 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Fluconazole | Fluconazole | 17 | suppressed |
| Hydrocortisone | Hydrocortisone | 17 | suppressed |
| Lovastatin | Lovastatin | 17 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 17 | suppressed |
| Bupropion Xl | Bupropion Hcl | 16 | suppressed |
| Estradiol | Estradiol | 16 | suppressed |
| Ibuprofen | Ibuprofen | 16 | suppressed |
| Klor-Con 8 | Potassium Chloride | 16 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 16 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 16 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Eszopiclone | Eszopiclone | 15 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 15 | suppressed |
| Mounjaro | Tirzepatide | 15 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 14 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 14 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 14 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 14 | suppressed |
| Vancomycin Hcl | Vancomycin Hcl | 14 | suppressed |
| Acetazolamide | Acetazolamide | 13 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 13 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 13 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 13 | 12 |
| Doxazosin Mesylate | Doxazosin Mesylate | 13 | suppressed |
| Levetiracetam | Levetiracetam | 13 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 13 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 13 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 13 | suppressed |
| Acyclovir | Acyclovir | 12 | suppressed |
| Atovaquone-Proguanil Hcl | Atovaquone/Proguanil Hcl | 12 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 12 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 12 | suppressed |
| Glipizide | Glipizide | 12 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 12 | suppressed |
| Metronidazole | Metronidazole | 12 | 11 |
| Tadalafil | Tadalafil | 12 | suppressed |
| Balsalazide Disodium | Balsalazide Disodium | 11 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Epinephrine | Epinephrine | 11 | suppressed |
| Eplerenone | Eplerenone | 11 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 11 | suppressed |
| Rybelsus | Semaglutide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $220.76 · 11 records | PFIZER INC. | ABRYSVO, CAPVAXIVE, COMIRNATY, EVENITY, FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE, FLUZONE HIGH-DOSE, GARDASIL 9, LEQVIO, Ozempic, PREVNAR 20, Rybelsus, SHINGRIX | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with GlaxoSmithKline, LLC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error